Which generation of targeted drugs does lorlatinib belong to?

Lorlatinib belongs to the third generation of ALK (anaplastic lymphoma kinase) and ROS1 (C-ros proto-oncogene1) targeted drugs, specifically used to treat ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). Compared with first-generation (such as crizotinib) and second-generation (such as aletinib, brigatinib) targeted drugs, lorlatinib shows significant advantages in dealing with drug-resistant mutations and brain metastasis.

As a third-generation targeted drug, lorlatinib was originally designed to overcome drug-resistant mutations that may arise after the use of the first two generations of drugs, especially the ALK gene mutation G1202R, which is a common type of mutation that causes the failure of first- and second-generation drugs. In addition, lorlatinib has a strong ability to penetrate the blood-brain barrier and can effectively treat brain metastasis, which is a common and difficult problem for many lung cancer patients.

Advantages and features of lorlatinib:

1.Ability to control drug-resistant mutations: Lorlatinib can inhibit a variety of ALK drug-resistant mutations (such as L1196M, G1202R), so it is still effective for patients who have experienced resistance to first- or second-generation TKI treatment.

2.Powerful brain metastasis control effect: Due to its strong blood-brain barrier penetration, lorlatinib has outstanding performance in controlling central nervous system metastases, which is difficult to match other first- and second-generation drugs.

3.Wide range of applications: Lorlatinib is not only effective for ALK-positive patients, but also has a therapeutic effect on some ROS1-positive patients, expanding the scope of indications for targeted therapy.

The development and application of lorlatinib marks the entry of ALK/ROS1 targeted therapy into a new stage, providing new options for patients with resistance to first- and second-generation drugs, and also significantly improving the survival rate and quality of life of patients.

xa0

Reference materials:

1.ALKTreatment Guidelines for Positive Lung Cancer - https://www.caca.org.cn/

2.American Society of Clinical Oncology (ASCO) Targeted Therapy Guidelines - https://www.asco.org/

3.State Food and Drug Administration Drug Instructions - https://www.nmpa.gov.cn/

4.UpToDateMedical Literature Database - https://www.uptodate.com/